Chagas Disease Clinical Trial
Official title:
Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)
BACKGROUND: Chagas Disease (ChD) remains as one of the most neglected diseases in the world,
with 8-10 million infected people and only one marginally effective therapeutic. The lack of
good biomarkers for active infection or clinical end-points poses a problem for assessing
the performance of new drugs or therapeutic interventions. Among the biomarkers, several
studies showed that Brain Natriuretic Peptide (NT-ProBNP) is accurate maker of left
ventricular systolic and diastolic dysfunction.
OBJECTIVE: Our long term goal is to establish The Sao Paulo-Minas Gerais Tropical Medicine
Research Center (SaMi-Trop) as a Center of Excellence for Neglected Infectious Disease
Research in Brazil. The Specific Aims are to begin that process by focusing on Trypanosoma
cruzi infection with the goal of finding an array of biomarkers that correlate with parasite
persistence and Chagas cardiac disease status that can be used to infer risk of disease
progression and death as well used as markers of cure (parasite eradication) or clinical
efficacy (stabilize or reverse cardiac damage) of novel drugs
METHOD: The investigators established a prospective cohort of 1,959 patients with chronic
Chagas cardiomyopathy (CCC). The study is being conducted in 21 cities of the northern part
of Minas Gerais state in Brazil, and includes a follow up of at least two years (baseline
and 24 months) . The evaluation included collection of socio-demographic information, social
determinants of health, health-related behaviours, comorbidities, medicines in use, history
of previous treatment for Chagas Disease (ChD), symptoms, functional class, quality of life,
blood sample collection and ECG.
RESEARCH STRATEGY
SIGNIFICANCE
The Sao Paulo-Minas Gerais Tropical Medicine Research Center (SaMi-Trop) consists of a
network of collaborating scientists in the States of Minas Gerais and São Paulo which has
been established for the purpose of developing and conducting research projects on neglected
infectious diseases in Brazil, with an initial focus on Chagas Disease biomarker, discovery
and validation. The SaMi-Trop represents a major challenge for focused research in neglected
diseases, with knowledge that can be applied in primary health care.
Chronic Chagas Cardiomyopathy (CCC) is the most important clinical presentation of Chagas
Disease (ChD), eventually affecting approximately 20% to 30% of those in the chronic phase
of the disease. CCC comprises a wide range of manifestations, including heart failure,
arrhythmias, heart-blocks, sudden death, thromboembolism and stroke [1]. Clinical
presentation typically varies widely according to the degree of myocardial damage and most
patients present a mild form of heart disease, frequently characterized only by the presence
of asymptomatic abnormalities on the ECG or in other complimentary exams [2]. Nonetheless,
when heart failure and/or severe arrhythmias manifest, the prognosis is ominous, with high
and premature mortality rates, typically in adult male patients,1 but also in the elderly
[3]. Indeed, when compared to patients with idiopathic cardiomyopathy, patients with CCC
have poorer survival, irrespective of other clinical and echocardiographic parameters [4].
Thus, the clinical course of Chagas heart disease is variable and identifying patients who
are at risk of progressive CCC and dying remains a challenge. Several longitudinal studies
performed in patients in the chronic phase of ChD demonstrated that many individual
characteristics predict an unfavorable prognosis. This subject was systematically reviewed a
few years ago and concluded that most studies were described in insufficient detail and/or
lacked minimal standards in reporting results. Results have been somewhat inconsistent in
different studies, and the best combination of clinical and laboratory variables predictive
of mortality has not yet been established [5].
A potentially helpful score to predict death was developed to permit the stratification of
risk in Chagas heart disease [6]. Six independent prognostic factors were identified, and
each was assigned a number of points: New York Heart Association class III or IV (5 points),
evidence of cardiomegaly on radiography (5 points), left ventricular systolic dysfunction on
echocardiography (3 points), non-sustained ventricular tachycardia on 24-hour Holter
monitoring or stress testing (3 points), low QRS voltage on electrocardiography (2 points),
and male sex (2 points) [6. Patients were classified in three risk groups according to the
final score: low risk (0 to 6 points), intermediate risk (7 to 11 points), and high risk (12
to 20 points). In the original study, the 5-year mortality rates for these three groups were
2 percent, 18 percent, and 63 percent, respectively.6 Although the score was successfully
validated in independent cohorts, [6,7] some important issues may arise. The derivation of
the score is complex and it is not easy to calculate during the medical consultation. To be
calculated, the patient must be submitted to several exams and procedures, including
clinical examination, ECG, Chest x-ray, echocardiogram and Holter monitoring or stress
testing. Most of these tests are not available in the rural areas, where most of ChD
patients live.
A simple score, based on widely available and low-cost tests, which could stratify the risk
of death without complex calculations, might be useful in the primary care setting, where
echocardiograms and Holter monitoring are not widely available. Easily obtained variables,
such as clinical features, BNP levels and ECG measurements, are good candidates as
biomarkers for developing a new simple predictive rule. Moreover, new biomarkers in blood,
related mainly to inflammation and the immune response, such as TNF-alpha, adhesion
molecules and other cytokines, may be determined to be potent prognostic factors and may be
useful in the future for further improvement in risk stratification in CCC.
METHOD
Design
Non-concurrent prospective open cohort study, with minimal follow-up of two years (baseline
and 24 months).
Outcome
Primary: death Secondary: hospitalization due to cardiac conditions; new ECG abnormalities
Study Population
Participants will be selected from patients evaluated by the Tele Minas Saude (TMS), the
state Tele Health System. Since the TeleHealth System is currently acting in support of the
Primary Care system, these patients are under the care of primary care physicians of the
Health Family Strategy, a public primary care program that has a high coverage in the state
of Minas Gerais.
The inclusion criteria are to be a client of the TMS TeleHealth System, be >18 years old,
have a positive history for T cruzi infection or Chagas disease, have an abnormal ECG and to
consent to participating in the research program.
The exclusion criteria include pregnancy or breast feeding, and any severe condition with
ominous prognosis that indicates a life expectancy of less than two years.
Sample size for patient accrual
Considering the minimal number of events per variable acceptable in a proportional hazards
regression analysis of 10 events per variable,8 and maximal number of studied variables of
ten, the number of events would be 100 in the whole study. Since the prediction model has to
be developed and validated and the whole sample will be divided in two, the number of events
should be 200. For a 2-year follow-up period and annual mortality rate of 5% in CCC (10% in
2 years), the calculated sample size is 2,000 subjects.
Since the TMS Telehealth system performs 25,000 ECGs each month (300,000 a year), that ECG
abnormalities typical of CCC are observed in 5% of these exams (1,250), and projecting that
10% of these patients would be recruited and agree to participate in this research program,
the calculated sample size of 2,000 patients will be recruited in a 16 months' accrual
period.
Follow-up
Follow-up will be conducted on a yearly basis, with standardized interviews and new ECG
exams performed after two years of baseline. Vital status and hospitalization will also be
ascertained by linkage of the study database with mortality and hospitalization databases of
the Ministry of Health.
Recruitment, initial evaluation and measurements
Patients will be recruited from among those that regularly attend the public primary care
service of State of Minas Gerais in places served by TMS Telehealth System. This system
provides teleconsultation and Electrocardiogram services (TeleECG), including interpretation
of all ECGs by a cardiologist in the University Hospital. A standardized simple form is
completed before the transmission of the ECG data to the University hospital and the
question "Do you know if you have Chagas disease?" will be added to this questionnaire.
Those who answer yes to this question and have abnormal ECG will be selected. A second visit
of the selected patients will be scheduled for performing a short questionnaire (including
the evaluation of the functional class) and for collecting blood samples. Blood samples will
be sent to a central laboratory for T. cruzi serology and BNP measurements, which will be
done by standard techniques. Other blood samples, including plasma for protein and antibody
studies and stabilized whole blood lysates for T cruzi PCR (Polymerase Chain Reaction), DNA,
will be stored at -80o C to enable batched testing for other biomarkers.
Electrocardiogram services (TeleECG)
The ECG performed in the town of origin of the patients will be sent to be assessed by the
TMS Telehealth System specialists. The Telecardiology activities were developed using a
digital electrocardiograph installed in the towns, at the Basic Health Units of the public
healthcare system. The examination was always carried out after being requested by a
physician. The ECG will be sent using communication software developed by the TMS Telehealth
System and will be analyzed by a on-duty cardiologist. The report will be sent to the
Primary Care facility and the ECG tracings will be transferred to ECG reading center. In
this ECG Reading Center, a software developed by Prof. Peter Mac Farlane, from Glasgow
University, will analyzes and codify the ECG (by the Minnesota Code) and compare to the
previous ECG, according to a validated algorithm [9]. All abnormal codes will be reviewed by
an experienced cardiologist.
Data analysis
The standardized mortality ratio (SMR) analysis and a survival analysis will be conducted.
The outcome death is death. Also, a survival analysis considering the secondary outcomes -
hospitalization due to cardiac conditions and new ECG abnormalities - will be run. The
development and validation of the prognostic model will follow current recommendations,
including the division of the sample in derivation and validation sample, and the use of
modern methods to evaluate the performance of the model [10,11]. Additionally, descriptive
spatial analysis using geographic distribution for the SMR and a Bayesian spatial model for
small area data will be run.
Innovation
Beyond the relevance of the main goal of this study, it has many unique and innovative
aspects, related to the use of knowledge and infra-structure developed for other projects
conducted by our research group:
1. The possibility of testing new biomarkers detected in other branches of this study or
in the NIH-sponsored REDS-II/III Chagas disease study.
2. The use of the infrastructure and the logistics of the TMS program, a state-wide
TeleHealth System coordinated by the University Hospital in the Brazilian state of
Minas Gerais
3. The use of the methodology of linkage between our databases and administrative and
mortality databases from the Health Ministry to complement the follow-up of the
selected patients
4. A standardized codification system of the ECGs, using the facilities of the ECG Reading
Center of the long-term longitudinal study on the health of 15,000 adult public
servants from Brazilian Universities (ELSA-Brazil).
New biomarkers ChD has a complex physiopathology and many immunological, inflammatory,
autonomic and micro-vascular processes have a role in the development or the progression of
the disease [12]. The investigators have described increased levels of macrophage
inflammatory protein (MIP-1alpha) and Tumor necrosis factor-alpha (TNF-alpha) in ChD
patients, [13-15] and that those patients with more severe forms have more elevated levels
[13]. Recently, in the ChD study (REDS-II), were studied 600 ChD patients and 500 controls
searching for biomarkers related to the disease and CCC. In a preliminary analysis, several
biomarkers including high sensitivity troponin, myoglobin, soluble vascular cell adhesion
molecule 1 (sVCAM-1), soluble intracellular cell adhesion molecule (sICAM) and
myeloperoxidase showed abnormal patterns in T cruzi seropositive and parasitemic donors and
CCC patients. These and other biomarkers, including those identified in the transcriptome
analysis are candidates to be studied in the whole cohort of 2,000 CCC patients in TMS
program or, alternatively, using nested case-control design.
Tele Minas Saude (TMS) Program, a state-wide public TeleHealth System
The TMS program is a partnership between the Minas Gerais State Health Department and the
State Research Agency (FAPEMIG) with six public universities of Minas Gerais: Universidade
Federal de Minas Gerais (UFMG), Universidade Federal do Triângulo Mineiro (UFTM),
Universidade Estadual de Montes Claros (UNIMONTES), Universidade Federal de Juiz de Fora
(UFJF), Universidade Federal de São João del-Rei (UFSJ) and Universidade Federal de
Uberlândia (UFU), forming the Teleassistance Network of Minas Gerais. Created from a
telehealth pilot project in cardiology (2006), later expanded to other specialties and
villages and transformed into permanent telehealth service, subsidized by the state
government in 2009 [16-18].
The objective is to support infrastructure projects of state public health, initially
deployed to support the Primary Health Care and Family Health Teams [16]. At that stage, had
as main objective to assist professionals in their daily work to improve access to
specialized services, reducing and qualifying referrals of patients to secondary and
tertiary care. The main activities offered are a) duty of teleconsultation offline in
various medical specialties, nursing, dentistry, physiotherapy, psychology, pharmacy and
nutrition, b) duty in telecardiology to analyze electrocardiograms (ECGs) and provide
teleconsultations online for critical clinical cases c) technical support online and
offline, d) permanent education through workshops and training and e) continuous monitoring
of system operation in the municipalities.
So far, the program was implemented in 608 municipalities in the state corresponding to 732
telehealth sites. The primary care units in the villages were equipped with computers,
electrocardiograph, digital printer and digital camera. Universities were equipped with
workstations and videoconferencing equipment. Since 2006, over 20,000 teleconsultations were
conducted and 600,000 ECGs analyzed by experts. These telehealth activities prevented the
displacement of patients in 78% of the cases [16].
Linkage of databases The Brazilian Health System is characterized by coexistence of a
universal public health system (70-80% of coverage) and a supplementary private network.
Mortality data from all Brazilians and from hospitalizations in the public health system are
stored in large databases owned and managed by the Health Ministry. Investigators developed
a methodology for searching these databases for specific subjects using probabilistic
linkage methods. The probabilistic strategy we developed has high accuracy, with a
sensitivity of 90.6% and specificity 100% [19]. This method will be used in a complimentary
way to direct follow-up.
ECG Reading Center ECG interpretation is subjected to substantial intra- and inter-observer
variability. To overcome this problem, a standardized ECG code was developed 50 years ago 20
and has been widely used in epidemiological studies. The visual classification of the ECG
using the Minnesota code, nonetheless, is time consuming. The investigators created a ECG
Reading Center for the Elsa study, a 10-year longitudinal cohort study of 15,000 public
employees of Brazilian Universities. For this ECG Reading Center, was installed a software
developed by Prof. Peter MacFarlane, from Glasgow University, that analyzes, codifies and
compares the ECG with previous tracings, according to a validated algorithm [9]. This system
will be used in the present project.
Preliminary Studies
Diagnostic and prognostic value of BNP In 2002, investigators described, in a study
published by The Lancet, that blood levels of BNP are inversely correlated to the systolic
left ventricular (LV) ejection fraction, the most used index of LV function in ChD [21]. In
patients with abnormal ECG and/or chest X-Ray, BNP elevation had a positive predictive value
of 80% and a negative predictive value of 97% for the detection of patients with depressed
left ventricular ejection fraction [21]. This results were confirmed in the following years
by several other studies by our research group [22-26]. A diagnostic strategy including ECG
and BNP performed better than the classical approach with ECG and chest X-Ray [24].
Moreover, BNP was also a marker of ventricular arrhythmia [26] and diastolic dysfunction
[22,27].
More recently, was described that BNP levels were strong predictors of the risk of death
[28] and in a cohort of 1,398 indwelling elderly from the city of Bambuí, in the state of
Minas Gerais, Brazil [28]. The hazard ratio for death was 1.27 for each unit of
log-transformed BNP level (95% confidence interval (CI: 1.11, 1.45) among infected persons,
independent of potentially confounding factors. Infected persons with baseline BNP levels in
the top quartile had a risk of death twice that of persons in the bottom quartile (hazard
ratio = 2.07, 95% CI: 1.29, 3.32). In the same population, was found that BNP alone or in
association with atrial fibrillation had prognostic value for stroke mortality in T. cruzi
chronically infected older adults [29].
Electrocardiographic measures and prognostic models The ECG is the single most important
exam in CCC. Numerous epidemiological studies have shown that patients with a normal ECG
have an excellent medium-term survival [30,31]. The greater the number and severity of ECG
alterations registered in a same tracing, the more advanced the myocardial damage possibly
is, and the worse the prognosis should be [12]. We have shown that the QRS duration is
moderately correlated with the LV ejection fraction [32] and that, during the follow-up of
these patients, the increase in the duration of the QRS complex and the appearance of new
electrocardiographic alterations may help in identifying patients with a significant
decrease (of 5% or more) in left ventricle ejection fraction [33].
Based in the well-known prognostic value of LV ejection fraction and the presence of
ventricular tachycardia, [5] was proposed an alternative approach to the well established
Rassi's score, [34,35] considering only three risk factors: left ventricular ejection
fraction < 50%, ventricular tachycardia at either stress testing or Holter monitoring, and
QRS > 133 ms at ECG (or filtered QRS > 150 ms at signal-averaged ECG).34,35 Low risk group
has zero or one risk factor (5-year mortality: 1%), intermediate risk, two factors (20%
mortality), and high risk, all three factors (50% mortality). This simplified prognostic
score had an excellent performance in predicting death in a study with 74 months of follow
up (c statistic 0.92) and it may be an attractive alternative to the established six-factor
score.
More recently, the investigators showed that T-wave amplitude variability (TWV), a
sophisticated ECG-derived measure of repolarization variability, is independently related to
the risk of death in ChD [36]. They have also studied the prognostic value of several new
echocardiographic measures [37-39] which could be of physiopathological and clinical
relevance, but are not possible to be used for ambulatory patients in the rural area.
Kaplan-Meier curves demonstrating mortality in Chagas disease patients Classified according
to the presence prolonged of QRS > 133 ms at ECG; Classified according to a risk score in
which each of the following factors is worth one point: ventricular tachycardia at either
stress testing or Holter monitoring, left ventricular ejection fraction < 0.50, QRS > 133 ms
at ECG. Low risk group has zero or one risk factors, intermediate risk, two factors, and
high risk, all three factors.
Summarizing, although we and others investigators have extensively studied prognostic
markers in Chagas disease and CCC, there is no definite simple, low-cost prognostic model
available to be used in the primary care setting. Standard ECG and BNP levels are good
candidates to be selected in this simplified predictive model.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01162967 -
Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
|
Phase 2 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Active, not recruiting |
NCT04024163 -
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
|
Phase 3 | |
Recruiting |
NCT05868005 -
Delivering a Multi-disease Screening Tool to Migrant Populations
|
N/A | |
Completed |
NCT03892213 -
Pharmacokinetic Drug-Drug Interaction Study
|
Phase 1 | |
Recruiting |
NCT00875173 -
Selenium Treatment and Chagasic Cardiopathy (STCC)
|
Phase 3 | |
Recruiting |
NCT03704181 -
Colchicine for Patients With Chagas´ Disease( B1 Stage)
|
Phase 2 | |
Active, not recruiting |
NCT03378661 -
BENDITA BEnznidazole New Doses Improved Treatment and Associations
|
Phase 2 | |
Completed |
NCT01927224 -
Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
|
Phase 1 | |
Completed |
NCT01006486 -
Outcomes of an Anticoagulation Clinic in an University Hospital
|
Phase 4 | |
Completed |
NCT00123916 -
BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
|
Phase 3 | |
Completed |
NCT02516293 -
Cardiac Rehabilitation in Chagas Heart Failure
|
Phase 2/Phase 3 | |
Completed |
NCT02517632 -
Physical Exercise Program in Chronic Chagas Heart Disease
|
Phase 3 | |
Recruiting |
NCT02099903 -
Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease
|
N/A | |
Completed |
NCT01874795 -
Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure
|
N/A | |
Completed |
NCT01006473 -
Exercise Training in Chagas Cardiomyopathy
|
Phase 4 | |
Completed |
NCT02386358 -
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial
|
Phase 3 | |
Not yet recruiting |
NCT05477953 -
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
|
||
Completed |
NCT02346123 -
Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy
|
N/A | |
Recruiting |
NCT02295215 -
Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction
|
N/A |